Navigation Links
For Moderate to Severe Psoriasis, Thought Leaders' Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
Date:6/24/2013

BURLINGTON, Mass., June 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists in the United States and Europe agree that a drug's effect on psoriatic plaques at 12-16 weeks is one of the attributes that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that the emerging biologics with novel mechanisms of action that target IL-17 have the potential to offer improvements over sales-leading adalimumab (AbbVie/Eisai's Humira) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Which Clinical Attributes Will Most Effectively Position Emerging Agents Against the Market Leader, Adalimumab? also finds that surveyed U.S. and European dermatologists and U.S. managed care organization (MCO) pharmacy directors consider therapies with a lower risk of serious infections than current therapies to be one of the greatest unmet needs in moderate to severe psoriasis. Interviewed thought leaders do not believe any emerging therapy has yet demonstrated clear potential to fulfill this unmet need. However, they are optimistic that agents with more-targeted mechanisms of action, including the IL-17 inhibitors, may offer improved safety compared to those that target multiple molecules or molecules that affect multiple downstream pathways.

The findings also reveal that more MCO pharmacy directors are willing to grant favorable formulary status to therapies that offer improvements in safety compared to the number who would grant this status to agents with improvements in efficacy. However, for drugs that are priced at a premium to adalimumab, MCO pharmacy directors indicate that improvements in the risk of serious infections will need to be substantial to secure reimbursement.

"When asked about factors influencing their treatment decisions, surveyed U.S. and European dermatologists assigned a high weight to a therapy's effect on psoriatic plaques at 12-16 weeks. However, they did not identify this attribute as an area of high unmet need," said Decision Resources Analyst Laura Croal, Ph.D. "The current market contains several biologic therapies with high levels of plaque clearance at 12-16 weeks. Greater unmet need was indicated for improvements on serious infection rates and sustained response rates beyond one year. Drug developers who invest in pivotal trials that extend to 52 weeks and then follow patients through several years of treatment may be in a position to fulfill these remaining unmet needs and differentiate their therapies in this increasingly crowded market."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
4. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
5. AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
6. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
7. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... Dr. Vivek Ahuja , George ... phen Schmidt Join the Growing Organization ... for life sciences, today announced key new leaders have joined the ... a growing business.  This will bolster the company,s safety business unit ... ArisGlobal in the position of Vice President - Safety. George has ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Coast Dental Fort Stewart is celebrating its grand opening with an open ... Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, and ... the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County ... Dr. Daniel A. Potter -- are proud of the recent release of their 2014 ... April, SART published the latest verified data for 375 U.S. member clinics. ...
Breaking Medicine News(10 mins):